Recently, Huawei has released a series 5.5G Information related to technological breakthroughs continues to attract market attention. Huawei will 2024 Launched for commercial use in 5.5G Full set of network devices, also known as 5.5G In terms of uplink and downlink rates, latency, deterministic experience, etc., compared with traditional network capabilities 10 Double improvement. Market views generally believe that this is 5.5G Commercialized signals are set to drive a new round of demand growth for equipment manufacturers and communication device suppliers.   For the primary market, 5.5G Technological breakthroughs can have a 5G What impacts does the industrial chain bring about? Which areas are the key investment directions for this year, and what opportunities exist? From the perspective of investment directions and rounds, what new trends are there compared to before this year?     Frost & Sullivan Frost & Sullivan Mr. Lu Jing, Partner and Managing Director of Frost & Sullivan's Greater China Region (hereinafter referred to as 'Frost & Sullivan'), was interviewed   Interview with the Sci-tech Innovation Board Daily, discussion 5G Industrial development trends.   * Click "Read the Original Article" at the end of this text to read the complete report. Sci-Tech Innovation Board Daily Q For the primary market, 5.5G Technological breakthroughs can have a 5G What impacts does the industrial chain bring about?   5.5G Upstream ultra-wideband, broadband real-time interaction, and communication perception fusion capabilities are added, enhancing 5G New scenarios have been expanded based on the existing ones, ranging from supporting Internet of Everything to driving intelligent Internet of Everything, with significant improvements. 5G Network capabilities and industrial innovation capabilities. 5.5G The realization of commercial implementation will drive the development of related industrial chains. By then, domestic suppliers of devices such as base station antennas, vibrators, and filters, operators, and application developers will all benefit from it. In addition, 5.5G It will enhance the speed and reliability of mobile communications, and at the same time drive the development of various application scenarios such as intelligent connected vehicles, virtual reality, and industrial Internet. Q What areas do you think are the key investment directions this year, and what opportunities exist? 5.5G The development is aimed at improvement 5G+ Applications, with this year's investment focus shifting from infrastructure construction 5G+ Applications and their adaptations 5.5G Key technology R&D. Leveraged by 5G The network features high bandwidth, low latency, and high concurrency capabilities. 5G+ Applications such as autonomous driving, remote control driving, wireless robots, remote medical diagnosis, connected drone inspections, and security will see rapid development. At the same time, 5G The development and maturity of related infrastructure will contribute to the creation 5G Fully connected factory, implemented 5G A virtuous cycle with industrial Internet. In addition, around 5.5G The key adaptation technology research and development involves technologies such as high-frequency bands, large bandwidths, low latency, network slicing, and edge computing, which will also become the focus in the post- 5G New opportunities for the development of the times. Q Looking at investment direction and rounds, what are the new trends compared to before this year? since 2020 starting from 5G The industry has seen an investment peak. Since the beginning of this year, China 5G Relevant investments have passed their peak period and are gradually slowing down, 5.5G The commercialization is expected to drive the industry into another wave of growth with both volume and price increases. In terms of investment direction, as 5G With the maturity of technology and the gradual improvement of the hardware industry chain, China enters the post 5G era, 5G The focus of industrial development and investment has gradually shifted from infrastructure construction 5G+ Application development. Cloud VR/AR Applications such as connected vehicles, intelligent manufacturing, smart energy, wireless healthcare, wireless home entertainment, connected drones, and smart cities, and 5G The combination has become a new trend in current investments. *   This interview was published in   Sci-tech Innovation Board Daily APP   Reporter: Yu Shiqi, original title:    5.5G Coming soon! Leading companies in the primary market are active in financing State-owned assets from Sichuan and Shenzhen step in    ">

2023 Shanghai International Biomedical Industry Week 10 month 16 day, 2023 The opening ceremony of the Shanghai International Biomedical Industry Week (referred to as 'Industry Week') was held at the Zhangjiang Science Hall in Shanghai. This year's Industry Week lasts for five days and is themed 'Working Together for a Shared Future, Full of Vitality'. Adhering to the concept of 'high-end, distinctive, and international', it aims to set industry benchmarks with innovative achievements, lead industry trends with leading enterprises, boost industry enthusiasm through rich activities, and implement the purpose of the event through in-depth exchanges. 1 The high-specification opening event, nearly 40 The event consists of high-level concurrent activities and will host a series of Industry Week events throughout the year, forming a “ 5+360 " (i.e., Industry Week 5 Tianjin Central Activity 360 The activity pattern of regular activities (daily routine activities). This year's Industry Week brought together thousands of heavyweight guests from the global biopharmaceutical field. Top experts from academia, including representatives of international organizations such as the International Pharmaceutical Federation (FIP) Chair Paul Sinclair (Paul Sinclair) , 2022 , 2001 Carl Barrie Sharpless, two-time Nobel laureate in chemistry (K. Barry SHARPLESS) Academicians of the Chinese Academy of Sciences Chen Kaixian and Jin Li, Academicians of the Chinese Academy of Engineering Chen Sajuan and Yang Shengli, Professor Lu Bai from the School of Pharmacy at Tsinghua University, and nearly 30 Academicians and experts from other fields discussed cutting-edge tracks; over a hundred iconic domestic and international biopharmaceutical entrepreneurs, such as Roche Group Chairman Jean-Pierre Sauvagnat and Moderna CEO Stefan Neuberger · Bäser, discussed international opportunities; representatives of leading investment and financing, ecosystem service providers, such as Frost & Sullivan ( Frost & Sullivan Frost & Sullivan, abbreviated as 'Frost & Sullivan', E Fund, BCG Boston, McKinsey, JPMorgan Chase, and the world's four leading accounting firms are jointly paying attention to industry hotspots, focusing on global industrial innovation trends, working together to create an open and integrated industrial landscape, and delving into the future of industries with high-quality development. 10 month 17 day, 2023 The Forum on Supporting the High-quality Development of the Biopharmaceutical Industry with an Innovative Medical Insurance System, one of the concurrent activities of the Shanghai International Biomedical Industry Week, was successfully held at the Shanghai Hengshan North Suburb Hotel. The forum focused on how to further advance the supply-side reform of medical services, encourage biopharmaceutical enterprises to innovate, and promote Shanghai's efforts to build a globally influential innovation hub for the biopharmaceutical industry, aiming to assist in achieving sustainable development of the medical security system. This forum is guided by the Shanghai Municipal Commission of Economy and Informatization, the Shanghai Municipal Medical Security Bureau, and the People's Government of Baoshan District, Shanghai. It is co-hosted by the Shanghai Biomedical Industry Promotion Center, the Shanghai Medical Centralized Bidding and Procurement Affairs Management Office, the Shanghai Baoshan District Economic Committee, and the Shanghai Baoshan District Medical Security Bureau, and organized by R & D Guest. Zhang Xiong, Deputy Secretary-General of the Shanghai Municipal People's Government; Xia Kehua, Secretary of the Party Leadership Group and Director of the Shanghai Medical Security Bureau; Wang Nai, Standing Committee Member and Deputy District Mayor of Baoshan District; Xue Sasa, Deputy District Mayor of Baoshan District; Zhang Chao, Member of the Party Leadership Group and Deputy Director of the Shanghai Medical Security Bureau; Yu Baorong, Professor at the School of Insurance of the University of International Business and Economics; Li Xin, Deputy Dean and Professor of Pharmacy at Nanjing Medical University; Hou Lei, Global Managing Partner at McKinsey; RDPAC Guests attending the forum included Chief Executive Officer Kang Wei, Secretary-General of the Pharmaceutical Promotion Association Feng Lan, General Manager of Magnesium Health Kangfu Zhiyao He Zhixiang, General Manager of China Life Reinsurance Shanghai Branch Gu Xiu, General Manager of the Life Insurance and Property Insurance Department of China Taiping Life Insurance Yuan Xudong, Director of Health Affairs and Market Access at Boehringer Ingelheim Han Ting, and Head of Health Economics and Real World Research in the Asia-Pacific Region at Aikunwei Xie Yang.   Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, was invited to attend the forum and delivered a speech on 'Analysis of the Current Development Status of Innovative Payments'. He also served as the moderator of the roundtable forum, exploring with the participants how diverse payment mechanisms can drive the innovative development of the biopharmaceutical industry. Deputy Secretary-General of the Shanghai Municipal People's Government Zhang Xiong       Zhang Xiong, Deputy Secretary-General of the Shanghai Municipal People's Government, delivered a speech at this forum. In his speech, he stated that the development of the biopharmaceutical industry cannot be separated from the full-chain support of innovation chains, industrial chains, talent chains, and capital chains, and even more so from stable market expectations.   This year, Shanghai has introduced a number of measures to support innovation in the pharmaceutical industry, especially focusing on empowering the innovative development at the front end of the industry by improving the payment and application mechanisms at the back end of the pharmaceutical industry. For example, further improving the diversified payment mechanism and supporting the development of innovative drugs and medical devices “ 28 The measures involve establishing a diversified payment mechanism for innovative drugs and medical devices through basic medical insurance and commercial health insurance. This promotes the inclusion of more high-quality innovative drugs and medical devices into the payment scope, facilitates the supply-side reform of medical services, enhances the accessibility and affordability of innovative drugs and medical devices, guides the positive development expectations of biopharmaceutical enterprises, and at the same time aids in the development of Shanghai's insurance and finance industry. These practical measures have sent out positive market signals, playing a role in stabilizing expectations and boosting confidence for the development of pharmaceutical enterprises. Partner and Managing Director of Frost & Sullivan Greater China Region fattening   During the keynote speech session, Mao Hua delivered a presentation focusing on "The Current Development Status of Innovative Payments." He pointed out that there is still significant room for improvement outside basic medical insurance, and innovative payments are integrated into new drugs. / The extended lifecycle after device approval for marketing can effectively reduce the economic burden on patients.   Looking at the medical insurance markets of developed countries and regions around the world, foreign innovative payment systems are maturely developed. Diverse models such as charitable drug donations, financial payments, and innovative commercial health insurance coexist, effectively meeting the diverse needs of the public.   Mao Hua said that with the deepening of population aging, China's healthcare system is under tremendous pressure, and per capita medical expenditure is still at a relatively low level compared to developed countries. In recent years, basic medical insurance has improved its basic security capabilities through measures such as improving the selection mechanism and refined management. 2022 The total number of drugs in the medical insurance catalog for the year reached 2,967 plant 111 The number of newly added drugs to the catalog saw an average price cut of 60% At the same time, it supports innovative access, actively including innovative drugs with high clinical value, significant patient benefits, and excellent economic evaluations in medical insurance negotiations. 2022 Among the newly added drugs in the annual catalogue, 23 It was newly listed back then 24 A major innovative drug from a certain country has been included in negotiations. "The personal portion of medical expenditures in our country is relatively high, and the potential for commercial insurance compensation expenditures remains untapped. At the same time, our country's commercial medical insurance coverage for pre-existing conditions and patients with chronic illnesses is quite insufficient," Mao Hua further stated.   "We can also see that at this stage, our country is actively exploring innovative payment models and accelerating the construction and improvement of an innovative medical security payment system, such as PAP Models, medical stages, people's livelihood insurance, etc. In the future, driven by favorable policies and the joint efforts of biopharmaceutical companies, it is expected to promote industry ecosystem innovation, achieve sustainable development of the medical security system, realize high-quality development of the biopharmaceutical industry, and ultimately benefit more patients. Subsequently, Mao Hua served as the moderator of the roundtable. He discussed with He Zhixiang, General Manager of Magnesium Health Kangfu Smart Medicine, Gu Xiu, General Manager of China Life Reinsurance Shanghai Branch, Yuan Xudong, General Manager of China Taiping Life Insurance's Life and Property Insurance Department, and Han Ting, Director of Health Affairs and Market Access at Boehringer Ingelheim, focusing on 'Exploring Diverse Payment Mechanisms to Promote Innovative Development in the Biopharmaceutical Industry'. They explored how diverse payment mechanisms can play a role in the biopharmaceutical industry to facilitate innovation and development.   More wonderful moments from forums   About Frost & Sullivan's Life Sciences Practice The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life science industry. The Life Sciences Practice has a wide range of corporate clients in China and in the past 20 In the year, a vast customer network was established, accumulating extensive project experience in various subfields of life sciences. Project types include Knowledge Center projects (in-depth content, promotional activities). Pre-IPO financing project DCF model Valuation, Business Plan Services), IPO listing We provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, strategic consulting, etc. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized sub-fields such as pharmaceuticals and medical devices, attracting wide attention from investors.

10 month 4 day TikTok Indonesian e-commerce business has been officially shut down TikTok Shop The platform no longer provides trading services, and shopping needs to be redirected to external links. The shutdown is related to Indonesian policies. 9 month 27 Yesterday, Indonesia released 2023 Year 31 The Ministry of Commerce's Order No. [XX], stipulating that social commerce can only be used to promote the promotion of goods or services and prohibits payment transactions. Therefore, social media must divest from e-commerce operations. Cross-border e-commerce involves many countries. From the perspective of competitive landscape and future market space, how should we view Temu What is the development of cross-border e-commerce represented by it? What is the biggest challenge in the future?   Frost & Sullivan Frost & Sullivan Zhang Xiaojing, Executive Director of Greater China at Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan'), was interviewed by Wall Street Journal Insights to discuss the development of overseas markets for cross-border e-commerce in China.   * Click "Read the Original Article" at the end of this text to read the complete report. Wall Street Observations Q Pinduoduo Temu We are accelerating our overseas expansion, opening new sites almost every month. What are the main difficulties in such overseas expansion? Is it mainly about cargo scheduling and logistics? For cross-border e-commerce, logistics and supply chain management are difficult aspects of business operations. Due to the wide coverage of cross-border e-commerce and the numerous links involved, from domestic package reception to warehouse storage, sorting, packing, customs clearance, to last-mile delivery, all require cooperation with logistics companies and system construction. Different logistics methods have different prices, and the difficulty of returns and exchanges also varies. Therefore, how to choose the appropriate transportation method to control costs, how to manage cross-border supply chains effectively, and establish efficient logistics networks to ensure that goods reach consumers in a timely manner are challenges faced by cross-border e-commerce companies expanding overseas. In addition, overseas expansion will face challenges from international and local well-known brands, such as Amazon. ebay Wal-Mart, among others, typically possess a large market share, a wide range of products, and a convenient shopping experience. Therefore, when domestic e-commerce companies expand overseas, while ensuring that their brand image remains consistent globally, they also need to create localized content and advertising campaigns, find unique positioning in the market, align the brand with local culture and values, and attract more traffic. Thus, how to effectively promote and build a brand is also one of the challenges in overseas expansion for e-commerce. Q Cross-border e-commerce involves many countries. From the perspective of competitive landscape and future market space, how do you view the situation with Temu What is the development of cross-border e-commerce represented by? What is the biggest challenge in the future? With the customs announcement 2014 Year 56 number and day 57 The release of the announcement includes the addition of codes for customs supervision methods for cross-border e-commerce, and regulatory norms have been established for cross-border e-commerce imports and exports, marking the rapid expansion of China's cross-border e-commerce industry. 2015 In the year, the cross-border e-commerce market scale reached 5.4 trillion yuan, compared to 2014 Year-on-year growth 28.6% According to the latest data from the Ministry of Commerce, 2022 In [year], the market scale of cross-border e-commerce in China reached 15.7 trillion yuan, than 2021 year 14.2 Year-on-year increase of trillions 10.56% with Temu The development of cross-border e-commerce represented by [company name] shows that China's cross-border e-commerce has grown from scratch and has become a new engine driving foreign trade development. At present, the number of cross-border e-commerce entities in China has exceeded 10 Wanjia, cross-border e-commerce industrial park within the comprehensive test area, approximately 690 First, the import and export scale of cross-border e-commerce goods has increased significantly. The competition in the cross-border e-commerce industry is fierce, with well-known multinational e-commerce platforms offering consumers a variety of choices in terms of product categories, delivery range, and delivery timeliness. Therefore, providing customers with a more personalized experience and higher-quality customer service, as well as maintaining long-term contact with customers by offering discounts and promotions, are challenges that cross-border e-commerce will face in the future. In addition, local policy changes are likely to be the biggest challenge that cross-border e-commerce may face in the future. As Temu and Shein The product unit price is low, and the packages are light. Most of them are small parcels shipped directly. The value of a single package is mostly less than 800 US dollars. According to the US tariff exemption policy, as long as the value of imported goods purchased by US individual consumers 800 Below the US dollar, tariffs can be waived. This exemption policy applies to Temu and Shein and other e-commerce businesses focusing on cross-border small package services are very beneficial. U.S. Customs data shows, 2018 yearly 4.11 Hundreds of millions of goods entered the country through the "minimum declaration principle", 2022 Year achieved 6.85 hundreds of millions. Recently, due to Temu and Shein The explosive growth, with Temu and Shein E-commerce mainly engaged in this area has faced strict scrutiny by the US Congress's Committee on US-China Economic Security Review. The US may tighten its tariff policies against China or lower the threshold for tariff exemptions, which could have a certain impact on future cross-border e-commerce exports. Therefore, in the future, cross-border e-commerce enterprises need to closely follow policy changes in each country to ensure legal operations and timely adjustment of business models during rapid expansion of their businesses. *   This interview was published in Wall Street Journal Insights, with reporter Liu Baodan. The original title was:    TikTok E-commerce stumbles in Indonesia    ">

9 month 28 Today, Frost & Sullivan Frost & Sullivan The Digital Economy Sub-forum of the 2nd New Investment Expo & 17th Frost & Sullivan Global Growth, Tech Innovation and Leadership Summit (referred to as the 'Frost & Sullivan New Investment Conference') successfully concluded. The participants focused on 'Digital Economy and Industrial Integration: AI Accelerated Industry-wide Transformation ” explored new opportunities for digital economy investment and financing.   Zu Yaru, Global Managing Partner and Executive Director of the Board at Frost & Sullivan; Dr. Wang Xin, Global Partner and Chairman of the Greater China Region at Frost & Sullivan; Wang Chenhui, Managing Partner and Executive Vice President of the Greater China Region at Frost & Sullivan and Co-founder of LeadLeo; and LeadLeo Research Institute AI Yuan Xucong, Chief Analyst of the Industry, was interviewed by Reuters to discuss China AI Industry development. Reuters News Global growth consulting firm Frost & Sullivan said that in the process of China's economic transformation, artificial intelligence AI There will be huge investment opportunities in this field, but in China AI The industry is also facing significant challenges in the field of high-end chip manufacturing. "I believe that the area of sustainable development represents a huge opportunity for investment in China. The second big opportunity will be in the field of artificial intelligence," said Zou Yaru, Global Partner and Executive Director of the Board at Frost & Sullivan. 9 month 27 Opening tomorrow 2023 Frost & Sullivan said to Reuters at its annual New Investment Conference. Zu Yaru believes that with the transformation of the Chinese economy, all industries will shift from traditional ones to more technology-driven sectors, thus presenting huge investment opportunities. The core driving force behind all these transformations is artificial intelligence. "In fact, I believe we have far surpassed digital transformation. Digital transformation is essentially about connectivity." ... I believe that we have now passed through this stage, and I think the next era is AI "In an era of transformation," he said. He also stated that this transformation will be on a large scale, and at present, it is still in a very early stage. However, over time, every industry and all aspects of daily life will be affected to some extent. AI Impact. "Artificial Intelligence ( AI ) has the potential to become one of the most dynamic investment areas in China over the next decade, 'said Wang Chenhui, managing partner and executive vice president of Frost & Sullivan Greater China and co-founder of LeadLeo. And stated that this is mainly based on the strong support of the Chinese government, a wide range of application areas, AI Continuous technological progress, large volumes of data, and high-quality and powerful computing capabilities. He said that China has made remarkable development progress in the field of artificial intelligence, including algorithms, computing power, applications, and data; China is actively promoting AI Engineering, shall AI The deep integration of technology into the real economy helps different sectors achieve intelligent transformation and upgrading, bringing more innovation and competitive advantages to enterprises and society. Dr. Wang Xin, Global Partner at Frost & Sullivan and Chairman of the Greater China Region, told Reuters that currently, the number of listed companies in China is still relatively low compared to the total number of enterprises. "How to enable these high-quality (Chinese technology) enterprises to not only obtain financing but also be favored by investors, securing the funds needed for their strategic development and new product research and development, and solving the problem of technological innovation in our country is a very important topic," he said. According to the 2023 Year in China AI "White Paper on Technology-Driven Enterprise Services", 2022 Year in China AI The industry market scale reaches 3,716 RMB 10 billion, accounting for about 20% ; At the same time, Chinese enterprise-level AI The solution market accounts for approximately the entirety of China AI market 77% , is expected to arrive 2027 The number will increase to about 83% .   china AI The industry faces constraints from high-end chips. As the competition in technology intensifies, China has been seeking self-reliance and control in key core technologies, but still faces practical constraints in hardware in frontier and high-end fields. "High-end AI The manufacturing of chips is in China AI One of the important challenges facing development is that China still does not possess the capability to manufacture high-end chips. This is mainly because manufacturing high-end chips requires a high level of technical expertise and mature manufacturing processes, which is a long-term accumulation process,” LeadLeo Research Institute AI "The industry's chief analyst, Yuan Xucong, said. He believes that China's supportive measures are unlikely to change the overall level and competitiveness of China's chip industry in the short term. To address these challenges, China can elevate the strategic status of the chip industry, strengthen cooperation with universities and research institutions, cultivate more chip technology talents, and actively engage in international cooperation. It can also attract international capital and technology into China's chip industry to promote innovation. Zu Yaru also said, AI In the future, there will be more options for chips, but this will also drive development in different countries AI Resistance and divergence points, AI The chip supply chain can dictate how it is implemented AI The solution has an impact, and over time, many countries will be involved AI chips, and ultimately manufacture these chips. He downplayed the impact of geopolitical tensions on Chinese investment, 'Technology is technology. Chip manufacturing capabilities can limit a country, but from the perspective of what these technologies can do, I believe the answer is no. Technology does not see geopolitical issues.' Generative AI in China (AI) In a frenzy, startups and tech giants release a vast amount of products almost every day, but investors warn that the industry is about to undergo a reshuffle as costs and profit pressures increase. *   This interview was published in   Reuters News   Reporter: Liu Luoyan, original title:    AI It will provide great opportunities in China's economic transformation, but there are still constraints on high-end chips    ">

9 month 27 day, 2023 The 2nd New Investment Expo and the 17th Frost & Sullivan Global Growth, Innovation and Leadership Summit (referred to as the 'Frost & Sullivan New Investment Conference' or 'Conference') grandly opened at the Shangri-La Shanghai Pudong Hotel. Frost & Sullivan Greater China 25 The anniversary celebration and VIP appreciation dinner were grandly held. The event site was packed with distinguished guests, bustling with activity. Representatives from various sectors including the government, academic associations, capital institutions, industry leaders, mainstream media, and higher education institutions gathered together to celebrate this occasion. As the best growth partner with industry depth and breadth, 25 Over the past year, Frost & Sullivan has pioneered 'Full-Service Investment Management (Total Investment Management, TIM "Providing comprehensive investment and financing services as well as various other professional consulting services for enterprises has made us a leading company in the field of investment and financing strategy consulting in China. We have served over 10,000 enterprises for listing and financing; we have established a market position confirmation system and pioneered the concept of “" FSBV The 'Frost & Sullivan' Brand Value Model&rddquo; has been adopted by over 500 The enterprise provides market position confirmation and brand valuation services. Frost & Sullivan's remarkable achievements are inseparable from the recognition, support and assistance of all clients and partners. This is especially true for the establishment of Frost & Sullivan Greater China. 25 On the occasion of our anniversary, to express our sincere gratitude to all our customers and partners, we are presenting the Frost & Sullivan Greater China Region 25 Anniversary Special Contribution Award". Mr. Zou Yaru, Global Partner and Executive Director of the Board at Frost & Sullivan Mr. Aroop Zutshi Dr. Wang Xin, Global Partner and Chairman of Greater China at Frost & Sullivan, together with Ms. Zhao Yan, Honorary Chairperson of the Frost & Sullivan's Expert Committee on Specialized and Emerging Industries, Chairman and General Manager of Huaxi Biotech, Mr. Yang Guoping, Chairman of the Frost & Sullivan Growth Strategy Expert Committee, Secretary of the Party Committee, Chairman and President of Mass Transit (Group) Co., Ltd., Chairman of the Board of Directors of Shanghai Mass Transit Public Utilities (Group) Co., Ltd., Dr. Liu Jun, Chairman of the Frost & Sullivan's Expert Committee on Specialized and Emerging Industries, Chairman of Rilian Technology, Mr. Xu Hui, Chairman and Executive Director of Innovation Qizhi, Chief Executive Officer of Frost & Sullivan's Growth Strategy Expert Committee, and Mr. Bi Shunjie, Partner in Charge of Business in Greater China at EY, presented certificates and trophies.   Ms. Zhao Yan, Huaxi Biotechnology Co., Ltd. (Stock Code: 688363.SH Chairman and General Manager. 2000 In [year], Ms. Zhao Yan came into contact with the field of microbial fermentation and decided to invest in Huaxi Biotechnology. Since then, she has led the company to be the first to achieve large-scale production and industrial application of hyaluronic acid fermentation. Currently, Huaxi Biotechnology has become a globally leading biotechnology and biomaterials company driven by synthetic biology technology, with the industrial scale of hyaluronic acid ranking first in the world. The company mainly focuses on the development and industrial application of bioactive substances such as functional sugars, proteins, peptides, amino acids, nucleotides, and natural active compounds that contribute to life health. The company adheres to the corporate development logic of 'science & technology & product & brand'. It has currently established six R&D platforms including a synthetic biology R&D platform, microbial fermentation platform, application mechanism R&D platform, pilot-scale transformation platform, cross-linking technology platform, and formula process R&D platform, vigorously promoting the integration of 'industry-university-research' and accelerating the industrialization and market transformation of scientific research achievements. Ms. Zhao Yan is also an entrepreneur who loves art and is passionate about public welfare. She has successively founded the Minhang Public Welfare Art Museum and the 'Cloud Public Welfare' project, which focuses on China's original ecological culture. ✨ 2020 year 2 In January, Ms. Zhao Yan was honored to be named on the Forbes "China's Most Outstanding Businesswomen List". ✨ 2022 year 1 In January, Ms. Zhao Yan was named “ 2021 China's Economic Annual Figures' ” ✨ 2022 year 3 Month, Ms. Zhao Yan was honored with 2021 Annual title of 'National March 8th Red-Banner Holder'     Mr. Yang Guoping Chairman of the Frost & Sullivan Growth Strategy Expert Committee Mr. Yang Guoping, Dazhong Transportation (Group) Co., Ltd. (Stock Code: 600611.SH Party Committee Secretary, Chairman and President, Shanghai Volkswagen Public Utilities (Group) Co., Ltd. (Stock Code: 600635.SH ) (Public 01635.HK Chairman of the Board of Directors. Deputy to the 14th, 15th and 16th Shanghai Municipal People's Congresses, Shanghai Jiao Tong University MBA Master of Business Administration, Senior Economist, Vice Chairman of Shenzhen Innovation Investment Group Co., Ltd., Honorary President of Shanghai Young Entrepreneurs Association, Vice President of China Taxi and Car Rental Association, President of Shanghai Microfinance Association, Supervisor of Shanghai Zhejiang Chamber of Commerce, Associate Professor at Shanghai Jiao Tong University Antai MBA President of the Alumni Association. National Model Worker, winner of the Ernst & Young Entrepreneur Award China Grand Prize, recipient of the Lifetime Honorary Award in the Chinese Road Transport Industry. Yang Guoping was at 1988 In response to the call of Shanghai to rectify the taxi industry, we established a new brand 'Dazhong'. Yang Guoping has built a diversified business portfolio with industrial and financial services, including mass transportation and public utilities. 2 A comprehensive service group centered around listed companies, Minsheng covers a range of businesses including integrated transportation, automotive services, big data, gas and water services, municipal construction, financial investment, etc., enjoying a very high brand awareness in key business districts across the country. The company also integrates rich offline resources and actively develops online businesses, aiming to build an urban lifestyle service platform. As an outstanding representative of Shanghai entrepreneurs and Zhejiang merchants, Yang Guoping has a wide influence in the industry. He has won various national awards multiple times. He also led the company to become the first in the service industry nationwide to receive the 'National Quality Management Award' and the 'Asia-Pacific Quality Award', setting an industry benchmark.   Dr. Liu Jun Chairman of the Frost & Sullivan Expert Committee on New and Emerging Markets Dr. Liu Jun, Ritec Technology (Stock Code: 688531.SH Chairman of the Board. National 'Ten Thousand Talents Program', Ministry of Science and Technology 'Double Creation Talents', Wuxi 'Taihu Talent'. Dr. Liu Jun holds 20 Year World 500 Strong work experience in e-commerce, with many years of overseas study and work experience holds 7 Long-term special consultant for internationally renowned foreign-funded enterprises, serving Xi'an Jiaotong University, Huazhong University of Science and Technology, etc. 5 Visiting professor at various universities, serving as an off-campus supervisor for postgraduate students at Southeast University and Shenzhen University. 2020 Winner of the Annual Ernst & Young Entrepreneur of the Year in Mainland China. Holds a personal invention patent 32 Items, published core papers 8 article.   Social Position: ✨ Vice Chairman of China Electronic Special Equipment Industry Association   ✨ Executive Vice President of Jiangsu Semiconductor Association ✨ President of Wuxi Specialized, Innovative and Emerging Enterprises Alliance ✨ Jiangsu Electronics Society SMT Chairman of the Special Committee ✨ Chairman of the Expert Committee of Shenzhen Electronic Equipment Industry Association ✨ United States IPC International Standardization Committee EMC chairman   Mr. Xu Hui Chair of the Frost & Sullivan & LeadLeo Science, Technology and Innovation Expert Committee Mr. Xu Hui is currently serving as the CEO of Qingdao Innovent AI Technology Group Co., Ltd. (Innovent AI 02121.HK Executive Director, Chief Executive Officer. Mr. Xu Hui is at IT Industry ownership 28 With years of sales, service, technology, and management experience, including a tenure as Vice President for Greater China at Microsoft SAP Vice President, Greater China Region IBM General Manager of the Greater China Finance Business Unit and Global Information Services Department, as well as Vice President of Wanda Network Technology Group. He has served in industries such as manufacturing, finance, retail, telecommunications, healthcare, education, and public services, and has a profound understanding of the development of various industries in the Chinese market. Mr. Xu Hui graduated from Shanghai Jiao Tong University with a Bachelor of Communication Engineering degree and obtained a Master of Business Administration in Senior Management from the Guanghua School of Management at Peking University. Mr. Xu has extensive industry connections and actively participates in social welfare activities such as education and charity. He is an enterprise mentor at Shanghai Jiao Tong University, Tongji University, and the School of Management at Fudan University. 2016 year 6 Since January, has served as a global golf leading brand and a listed company in Hong Kong Honma (Binhai Golf 06858.HK Mr. Xu Hui is currently an independent director of Frost & Sullivan. . Chairman of the LeadLeo Sci-Tech Innovation Expert Committee. He is 2019 In 2017, it was awarded the "Ram Charan Management Practice Award" selected by Harvard Business Review - Innovation and Entrepreneurship Practice Award", and 2020 In FastCompany Selected as China's Most Creative Business 100 One of the annual figures. Mr. Xu Hui 2018 year 2 Founded in January, InnoCentrix 2022 year 1 month 27 Led the company to successfully list on the Main Board of the Hong Kong Stock Exchange. Mr. Xu started his career in 2022 year 4 month 7 I was invited to participate in the State Council Economic Situation Expert and Entrepreneurs Symposium and spoke as a representative of private science and technology innovation enterprises.   Mr. Bi Shunjie Executive Member of the Frost & Sullivan Growth Strategy Expert Committee Mr. Bi Shunjie, Partner-in-Chief of EY Greater China.   Mr. Bi Shunjie has profound practical and consulting experience in industries such as retail, consumer goods, manufacturing, and transportation. He has extensive experience in auditing, business consulting, and corporate financing, providing consulting and auditing services for listed companies, mergers and acquisitions, restructuring, etc., for state-owned enterprises, foreign-funded enterprises, and private enterprises. Mr. Bi Shunjie has long been committed to building consensus on the entrepreneurial spirit within a broader social context. For many years, Mr. Bi has served as the co-chair of the China project of the Ernst & Young Entrepreneurship Awards, continuously enhancing the impact of the program and helping numerous enterprises and entrepreneurs in various industries gain more recognition and attention. This provides a reference and model for the economic and industrial transformation and upgrading of China in the new era. Mr. Bi Shunjie is also an active supporter of innovative and high-growth enterprises. He believes that high-growth enterprises are an important source of innovation and a crucial force for the healthy and sustainable development of the national economy.   Partners are the most important supporters and drivers of Frost & Sullivan's growth and development, and they are also the most cherished asset that Frost & Sullivan has ever had. Looking to the future, Frost & Sullivan will, with gratitude, a spirit of cooperation and the ambition for mutual success, sincerely look forward to advancing hand in hand with all partners. We will live up to the times, never forget our original aspirations, and jointly create an even brighter tomorrow!

The 2nd New Investment Expo 2023 and the 17th Frost & Sullivan Global Growth, Innovation and Leadership Summit were held again at the 'World Salon' in Shanghai on September 27-28, 2023. On September 28th, the 2023 Frost & Sullivan Global Growth, Innovation and Leadership Awards, Asia-Pacific Awards and China Awards were grandly announced at the Frost & Sullivan Life Sciences New Investment Summit Forum.   Based on research and analysis of the Chinese medical endoscope market over recent years, as well as studies and evaluations of related companies in the industry, the globally renowned growth consulting firm Frost & Sullivan (Frost & Sullivan, abbreviated as F&S) awarded Nanjing Nuoyuan Medical Devices Co., Ltd. the 'China Functional Endoscope Innovation Award', which was presented by Mr. Wang Chenhui, Managing Partner and Executive Vice President of Frost & Sullivan Greater China, to Mr. Cai Huiming, Founder of Nanjing Nuoyuan Medical Devices Co., Ltd.   Frost & Sullivan awarded Nanjing Nuoyuan Medical Devices Co., Ltd. ‘China Functional Endoscope Innovation Award’ Mr. Wang Chenhui presented the award to Cai Huiming, Founder of Nuoyuan Medical   Nanjing Nuoyuan Medical Devices Co., Ltd. focuses on precision medical technology and continuously develops a series of functional endoscope products Nanjing Nuoyuan Medical Devices Co., Ltd. (hereinafter referred to as Nuoyuan Medical) was established in 2011 and is a national high-tech enterprise integrating the research, development, production and sales of high-end medical devices and innovative targeted probes. Nuoyuan Medical is committed to meeting the clinical needs of precise tumor diagnosis and treatment, mastering core technologies in multiple aspects such as fluorescence endoscope design and manufacturing technology, endoscope imaging technology and platform integration technology, achieving efficient transformation and clinical application of technical achievements, developing functional endoscope products at an internationally advanced level, and its research team has innovatively explored ultra-high detection sensitivity of fluorescent tracers, especially cutting-edge technologies such as quantitative analysis function and tumor boundary sharpening, breaking through technical barriers such as real-time intraoperative detection of sub-millimeter-level micro-lesions and precise marking of tumor digital boundaries, providing a new solution for clinical formulation of more accurate surgical plans and reduction of damage to surrounding healthy tissues. At present, its surgical fluorescence imaging system and 4K endoscope fluorescence imaging system have been successfully launched, completing a multi-dimensional functional leap. At the same time, the composite product '4K 3D Endoscope Fluorescence Imaging System', integrating three functions of 3D, 4K and fluorescence, has been approved to enter the innovative medical device registration procedure.   Nanjing Nuoyuan Medical Devices Co., Ltd. focuses on theoretical and mechanistic research in fields such as molecular fluorescence, Raman spectroscopy, and artificial intelligence, and has multiple core research technologies underway Nuoyuan Medical has established an innovative model of 'simultaneous development of drugs and medical devices', utilizing its deep accumulation in drug research and development to develop the broad-spectrum fluorescent probe indocyanine green suitable for imaging systems; at the same time, using AI assistance and CADD technology, it has developed targeted fluorescent probes for multiple typical tumor receptors, among which the new generation of targeted 'Peme' fluorescent tracer is expected to bring important improvements in terms of improving the accuracy and effectiveness of tumor surgery, and improving the prognosis and quality of life of patients. Compared with similar foreign fluorescent tracers, 'Peme' fluorescent tracer has high specificity and can significantly reduce the false positive rate. At present, 'Peme' fluorescent tracer has obtained invention patent authorization in countries and regions such as China, the United States, Europe, and Japan. At the same time, Nuoyuan Medical further deepens its technical advantages in the field of molecular fluorescence, and the ongoing research on molecular fluorescence composite navigation technology deeply integrates molecular fluorescence and Raman spectroscopy, achieving a leap from tumor pathological boundaries to molecular gene boundaries through self-developed algorithms. In addition, Nuoyuan Medical continues to explore minimally invasive precision treatment solutions, integrating exclusive ablation simulation technology, conformal ablation technology and carbonization regulation technology to effectively solve clinical problems of tumor microwave treatment and achieve precise ablation throughout the preoperative, intraoperative and postoperative processes.   Nanjing Nuoyuan Medical Devices Co., Ltd., based on its leading position in the Chinese market, promotes international cooperation and market expansion Since its establishment in 2011, Nuoyuan Medical has undertaken more than ten national and provincial key research projects such as the 'National 13th Five-Year Plan Key Research and Development Program', 'National Major Scientific Instrument Development Project', 'National Ministry of Industry and Information Technology Artificial Intelligence Medical Device Innovation Task Announcement', and 'Jiangsu Province Key Core Technology Research Project'. At the same time, Nuoyuan Medical actively expands into the international market, and in terms of patent layout, it has authorized 77 domestic and foreign invention patents, achieving patent protection for the whole machine and core components. At the same time, Nuoyuan Medical has carried out strategic cooperation with international leading companies such as B&R in Germany to promote the registration of products in China, the United States and Europe.   About the Frost & Sullivan Life Sciences New Investment Summit Forum The 2023 Frost & Sullivan Life Sciences New Investment Summit Forum was held on September 27-28, with the theme of 'New Directions for the Future & Forge Ahead', bringing together more than 30 industry leaders, life science enterprises, investment institutions and professional service institutions, focusing on new investment and financing opportunities in life sciences, and jointly discussing the capital and industrial forces for enterprises to navigate through cycles. About the Frost & Sullivan China Innovation Award The Frost & Sullivan China Innovation Award is an acknowledgment of an enterprise's outstanding performance and achievements in technological innovation, market potential, customer service, brand, etc. The Frost & Sullivan team has nominated a group of competitive and excellent enterprises to the independent judging panel through methods such as in-depth interviews, industry analysis, and secondary research. The independent judging panel composed of third-party investment and financing experts, financial experts, bankers and well-known listed entrepreneurs conducts strict evaluations on the enterprises nominated by the Frost & Sullivan team and decides to award the 'China Functional Endoscope Innovation Award' to Nanjing Nuoyuan Medical Devices Co., Ltd.  

The 2023 Second New Investment Expo and the 17th Frost & Sullivan Global Growth, Innovation and Leadership Summit were held again at the 'World Salon' in Shanghai from September 27th to 28th, 2023. On September 28th, the 2023 Frost & Sullivan Global Awards for Growth, Innovation and Leadership, Asia-Pacific and China were grandly announced at the Frost & Sullivan Life Sciences New Investment Summit Forum.   Based on research and analysis of the Chinese oncolytic virus therapy market in recent years, as well as studies and evaluations of related companies in the industry, the globally renowned growth consulting firm Frost & Sullivan (Frost & Sullivan, abbreviated as: Frost & Sullivan) awarded Wuhan Binhuai Biotechnology Co., Ltd. (hereinafter referred to as 'Binhuai Biotech') the 'China Oncolytic Virus Therapy Leadership Award', which was presented by Dr. Wang Xin, a global partner of Frost & Sullivan and Chairman of the Greater China Region, to Mr. Liu Binlei, Chairman of Wuhan Binhuai Biotechnology Co., Ltd.   Frost & Sullivan awarded Wuhan Binhuai Biotechnology Co., Ltd. ‘China Oncolytic Virus Therapy Leadership Award’   Dr. Wang Xin presented the award to Mr. Liu Binlei, Chairman of Binhuai Biotech   Binhuai Biotech is a leading biopharmaceutical company in China in the research and development and production of oncolytic virus drugs Binhuai Biotech was established in 2010 by Dr. Liu Binlei, a key member of the original research team that has approved the market launch of the oncolytic virus T-VEC (Imlygic). It is a national high-tech enterprise specializing in the research and development, production, and technical services of new biological drugs. Currently, the company has established an oncolytic virus immunotherapy platform with independent intellectual property rights and a leading position in the industry, and has established production processes recognized by NMPA and FDA, enabling integrated production and research to meet clinical and industrialization needs.   Multiple oncolytic virus products have entered clinical trials, playing a therapeutic role against various solid tumors Binhuai Biotech's oncolytic virus candidate drug BS001 (OH2) injection was approved for IND by the Chinese NMPA in 2018, and then received FDA approval in North America on August 20, 2021, to conduct clinical trials for various solid tumors; it then received orphan drug designation (ODD) from the US FDA on July 28, 2022, and fast track qualification (FTD) from the FDA on June 22, 2023. BS001 injection is the world's first oncolytic virus candidate drug that has selected type II herpes simplex virus (HSV2) as a vector and entered phase III clinical research, and has been included by the CDE as a 'breakthrough therapy variety'. In addition to BS001, Binhuai Biotech's oncolytic virus product BS006 injection has also received FDA approval for clinical research. On August 4, 2023, Binhuai Biotech obtained the 'Drug Production License' A certificate for therapeutic biological products issued by the Hubei Provincial Drug Administration, indicating its leading position in the research and development and production of oncolytic virus drugs.   Integrated production and research, ten years of forging a core technology to drive the development of the oncolytic virus industry Binhuai Biotech's independently developed BS001 (OH2) injection has complete independent property rights, promoting the breakthrough of Chinese oncolytic viruses from 'non-existent' to 'existing'. Since its establishment, Binhuai Biotech has completed the entire process from POC to CMC to independent production, thereby realizing full closed-loop development and production of oncolytic viruses. Binhuai Biotech has advantages in the entire process of IND product application, new drug research and development lifecycle, GMP production, etc., and holds multiple core invention patents. With many advantages, it is expected to promote the progress of multiple oncolytic virus products.   About the 2023 Frost & Sullivan Life Sciences New Investment Summit Forum The 2023 Frost & Sullivan Life Sciences New Investment Summit Forum was held on September 27th - 28th, with the theme of 'New Directions for the Future & Forge Ahead', bringing together more than 30 industry leaders, life science companies, investment institutions, and professional service agencies, focusing on new investment opportunities in life science investment and financing, and jointly discussing the capital and industrial forces for enterprises to navigate through cycles. About the Frost & Sullivan China Leadership Award The Frost & Sullivan China Leadership Award is an acknowledgment of an enterprise's outstanding performance and achievements in technological innovation, market potential, customer service, brand, etc. The Frost & Sullivan team has nominated a group of competitive and excellent enterprises to the independent judging panel through methods such as in-depth interviews, industry analysis, and secondary research. The independent judging panel composed of third-party investment and financing experts, financial experts, bankers, and well-known listed entrepreneurs conducts strict evaluations of the enterprises nominated by the Frost & Sullivan team, and decides to award the 'China Oncolytic Virus Therapy Leadership Award' to Wuhan Binhuai Biotechnology Co., Ltd.    

The 2nd New Investment Expo 2023 and the 17th Frost & Sullivan Global Growth, Innovation and Leadership Summit were held again at the 'World Salon' in Shanghai on September 27-28, 2023. On September 28, the 2023 Frost & Sullivan Global Growth, Innovation and Leadership Awards, Asia-Pacific Awards, and China Awards were grandly announced at the Frost & Sullivan Life Sciences New Investment Summit Forum.   Based on recent research and analysis of the Chinese cell therapy drug market, as well as studies and evaluations of related companies in the industry, the globally renowned growth consulting firm Frost & Sullivan (Frost & Sullivan, abbreviated as: Frost & Sullivan) awarded the 'China Cell Drug Innovation Award' to Shihuli Biotechnology Co., Ltd. (hereinafter referred to as 'Shihuli Biotech'), with Dr. Xin Wang, a global partner at Frost & Sullivan and Chairman of Greater China, presenting the award to Dr. Yarong Liu, the founder of Shihuli Biotech.   Frost & Sullivan awarded Shihuli Biotechnology Co., Ltd. the 'China Cell Drug Innovation Award'   Dr. Xin Wang presented the award to Dr. Yarong Liu, the founder of Shihuli Biotech   Shihuli Biotech is a leading domestic biopharmaceutical company represented by TIL cell therapy Founded in 2019, Shihuli Biotech is a leading domestic company focusing on tumor immune cell therapy, represented by tumor-infiltrating lymphocytes (TIL) therapy. TIL therapy is a type of cell drug and is considered to have great innovative therapeutic potential in the field of solid tumor treatment. The company has multiple core technologies in TIL cell screening, amplification, and genetic engineering, which can be applied to the development of next-generation solid tumor TIL therapy.   Promoting TIL therapy into clinical practice, bringing new treatment prospects to Chinese solid tumor patients Shihuli Biotech's independently developed and produced TIL therapy treatment product GT101 injection officially obtained a clinical trial implied approval from the National Medical Products Administration in April 2022, becoming China's first TIL therapy product to enter clinical trials, and is currently about to enter the critical phase II clinical trial stage. On July 12, 2023, Shihuli Biotech's independently developed next-generation gene-edited TIL product GT201 injection, expressing membrane-bound cytokines, officially obtained a clinical trial implied approval from the National Medical Products Administration and entered the clinical stage. These innovative breakthroughs are expected to bring new treatment options to solid tumor patients.   Multiple core technologies, creating cancer treatment technologies with higher safety and better therapeutic effects Shihuli Biotech's TIL cell therapy technology relies on its own core R&D technology platform and has core advantages in TIL cell amplification, transfection, target screening, and gene knockout. Research data shows that the next-generation TIL therapy developed based on its core platform has stronger proliferation ability, better tumor-killing ability and cytokine release ability, as well as better persistence compared to traditional TIL therapy, effectively addressing the challenges faced by traditional TIL therapy. Shihuli Biotech's TIL cell therapy has shown good therapeutic potential in clinical trials targeting various advanced solid tumors and is expected to become a pioneering treatment product in the field of solid tumor cell drugs, bringing new treatment hope to cancer patients.   About the Frost & Sullivan Life Sciences New Investment Summit Forum The 2023 Frost & Sullivan Life Sciences New Investment Summit Forum was held on September 27-28, with the theme 'New Directions for the Future, Forge Ahead', bringing together more than 30 industry leaders, life science companies, investment institutions, and professional service providers. It focused on new opportunities for life sciences investment and financing, jointly discussing the capital and industrial forces for enterprises to navigate through cycles. About the Frost & Sullivan China Innovation Award The Frost & Sullivan China Innovation Award recognizes outstanding performance and achievements of enterprises in technological innovation, market potential, customer service, brand, etc. The Frost & Sullivan team nominated a group of competitive and excellent enterprises to the independent judging panel through methods such as in-depth interviews, industry analysis, and secondary research. The independent judging panel composed of third-party investment and financing experts, financial experts, bankers, and well-known listed entrepreneurs conducted a strict review of the enterprises nominated by the Frost & Sullivan team and decided to award the 'China Cell Drug Innovation Award' to Shihuli Biotechnology Co., Ltd.    

The 2023 Second New Investment Expo and the 17th Frost & Sullivan Global Growth, Innovation & Leadership Summit were held once again at the 'World Salon' in Shanghai on September 27-28, 2023. On September 28, the 2023 Frost & Sullivan Global Growth, Innovation & Leadership Awards, Asia-Pacific and China Awards were grandly announced at the Frost & Sullivan Life Sciences New Investment Summit Forum.   Based on the research and analysis of the Chinese disposable electronic hysteroscopy integrated diagnosis and treatment equipment market in recent years, as well as the research and evaluation of related companies in the industry, the globally renowned growth consulting firm Frost & Sullivan (Frost & Sullivan, abbreviated as: Frost & Sullivan) awarded 'Innovation Award for Disposable Electronic Hysteroscopy Integrated Diagnosis and Treatment Equipment in China' to Shanghai Yudu Medical Technology Co., Ltd. (hereinafter referred to as 'Yudu Medicine'). The award was presented by Mr. Wang Chenhui, Managing Partner and Executive Vice President of Frost & Sullivan Greater China, to Mr. Wang Chenfeng, Vice President of Shanghai Yudu Medical Technology Co., Ltd.   Frost & Sullivan has awarded Shanghai Yudu Medical Technology Co., Ltd. "China One-Time-use Electronic Hysteroscopy Integrated Diagnosis and Treatment Equipment Innovation Award" Mr. Wang Chenhui presented the award to Mr. Wang Chenfeng, Vice President of Yudu Medicine   Leading in minimally invasive gynecological diagnosis and treatment, Yudu Medical is committed to creating globally leading medical technologies and products for customers. Yudu Medical was founded in 2006. The company focuses on technology and product research and development in the fields of high-end endoscopes, medical ultra-high-definition imaging systems, medical special light imaging, gynecological flow cytometry big data software, gynecological pathology, and AI-assisted diagnosis and treatment in imaging. It has established long-term strategic cooperative relationships with domestic and international universities and research institutions, continuously increasing investment in R&D expenses and the introduction of R&D talents, and possesses a complete national sales network and channels.   "Immediate diagnosis and treatment", Yudu Medical Innovation provides disposable electronic hysteroscopy. Yudu Medical has targeted issues such as the long preparation time, difficulty in entering the uterine cavity, complex procedures, and risk of cross-infection with traditional hysteroscopic instruments. It has successfully developed a DOHIS disposable hysteroscopic overall solution. It features multiple innovations such as non-planar continuous convection, dual-pump constant-pressure uterine distension, intraoperative safe electrocoagulation, automatic biopsy under the microscope, segmented rapid tandem operation, intraoperative instrument shaping, rapid wall-penetrating surgery, and high-definition wide-angle surgical field. While inheriting the high-definition resolution of optical microscopes (the world's first disposable high-definition hysteroscope) and the ability for immediate diagnosis and treatment, it has achieved original technological breakthroughs such as simplified and efficient operations, rapid tissue sampling under the microscope, continuous maintenance of a high-definition surgical field, comprehensive management of hysteroscopic complications, and a significant increase in the success rate of non-anesthetic surgeries. It provides an innovative overall solution of 'immediate diagnosis and treatment'.   With a wide range of indications, the DOHIS disposable electronic hysteroscope provides innovative solutions. The Yudu Medical DOHIS disposable electronic hysteroscope product can be applied in multiple clinical scenarios such as abnormal uterine bleeding, endometrial evaluation and diagnosis and treatment of intrauterine diseases, cancer screening for endometrial cancer lesions, and post-abortion endometrial evaluation. It has a broad range of indications. Compared with traditional hysteroscopy, the DOHIS disposable electronic hysteroscope has more advantages in terms of cost, efficiency, and prevention of nosocomial infections: only one integrated device needs to be purchased, resulting in low procurement and operating costs; it saves time, reducing the time cost by 6 times compared to traditional equipment, and can meet the needs of a large number of outpatient patients; it is sterile packaged and disposable, reducing the risk of nosocomial cross-infection.   About the Frost & Sullivan Life Sciences New Investment Summit The 2023 Frost & Sullivan Life Sciences New Investment Summit Forum was held on September 27-28, with the theme of 'New Directions for the Future: Forging Ahead'. It brought together more than 30 industry leaders, life science companies, investment institutions, and professional service providers to focus on new investment opportunities in life sciences and explore the capital and industrial forces that enable enterprises to navigate cycles. About the Frost & Sullivan China Innovation Award The Frost & Sullivan China Innovation Award recognizes outstanding performance and achievements in technological innovation, market potential, customer service, brand, and other aspects by enterprises. The Frost & Sullivan team nominates a competitive group of excellent companies to the independent judging panel through methods such as in-depth interviews, industry analysis, and secondary research. The independent judging panel, composed of third-party investment and financing experts, financial experts, bankers, and renowned listed entrepreneurs, conducts a rigorous review of the companies nominated by the Frost & Sullivan team and decides to award the 'China One-Time Electronic Hysteroscopy Integrated Diagnosis and Treatment Equipment Innovation Award' to Shanghai Yudu Medical Technology Co., Ltd.  

Foodtalks Offline Salon   9 month 22 Today, with “Probiotics × Radiation Protection  | Racing to the Next Probiotic Frontier" Foodtalks The offline salon was successfully held at the Weikang Probiotics Research Institute. At the event, representatives from Weikang and Frost & Sullivan ( Frost & Sullivan Frost & Sullivan, abbreviated as 'Frost & Sullivan', Yili, Daily Bacillus, and experts from Jinduoduo jointly discuss the latest trends in the probiotic market, share the latest achievements of probiotics in radiation protection functions, analyze the pain points in probiotic product development, and explore product forms and concepts more suitable for consumers from a future perspective. Probiotics is a track full of opportunities. However, the continuous changes in market demand, the emergence of new technologies, and the constant adjustment of competitive landscape have all placed higher demands on industry professionals. To stand out, it has become particularly important to understand the development trends and competitive dynamics of the market.   Mr. Zhang Jian, Partner and Managing Director of Frost & Sullivan Greater China, was invited to attend the event with the following presentation:   Delivered a speech titled "Exploring the Next Growth Point in the Billion-Royale Probiotic Market," offering attendees a comprehensive insight into the probiotic industry from a global perspective. Through analysis of outstanding domestic and international cases, the speaker highlighted the standout tracks in the probiotic industry and analyzed its future development trends. Partner and Managing Director of Frost & Sullivan Greater China Region Zhang Jian   Zhang Jianjun first pointed out that, currently,     China adopts a list management system for edible mushroom strains. At present, group standards related to probiotic products have been released, but there are still no national standards for probiotics in a strict sense. In the future, the standard framework related to probiotics will become more standardized and perfect.     According to a study by Frost & Sullivan, the global probiotic market size is in 2022 Annual achievement 686 billions, expected to 2027 The year will exceed 10% The average annual compound growth rate is accelerating, exceeding 1,200 billions, while China will account for at least 25% market share.   Data from the Probiotics Branch of the Chinese Institute of Food Science and Technology show that Asia has the highest global consumption scale of probiotics, accounting for approximately 44% Second is Europe 24% North America 18% Highlighting the vigorous development momentum of the probiotic industry in the Asia-Pacific region. Among them,   By product type, beverage probiotics are expected to be the fastest-growing market.   Due to the accelerating pace of life and the increasing awareness of health, people are increasingly preferring to purchase convenient and easily consumable probiotic beverages;   By application area, health supplements are the largest segment in the global probiotic market.   As a natural food supplement, probiotics play an important role in preventing and improving many diseases, such as indigestion and immune system disorders.   Zhang Jian stated that thanks to the gradual improvement in people's living standards, per capita disposable income and purchasing power have continued to rise, and residents' consumption of probiotic products has also been continuously increasing. 2018 Year-end 2022 In [year], the market scale of probiotics in China was from 648 RMB 10 billion, steadily increasing to 1,123 Yuan, with an average annual compound growth rate of 15% Looking ahead, with the continuous introduction of more diverse probiotic products and the increasing appeal of younger consumers due to the variety of product categories and functions, the probiotic market is expected to be further driven. It is anticipated that the market size of probiotics in China will further expand in the future, with domestic products gradually replacing imported ones, and the industry will become more standardized. In terms of per capita consumption, 2022 In the year, in the global probiotic market, Italy had the highest per capita consumption, reaching 10.6 US dollars, followed by the United States, with per capita consumption of probiotics reaching 6.8 US dollar, ranked third is Australia, with per capita consumption of probiotics reaching 6.0 US dollar.   "The per capita consumption of probiotics in China is only 0.4 The US dollar, compared to other countries, has significant room for improvement in per capita consumption of probiotics in China." Zhang Jian said. From the perspective of major application markets, food and beverages are the largest application area for probiotics, mainly used in the fields of food, beverages (including dairy products), etc.; health supplements, which include probiotics, are the second largest area, including infant health products.   "The public health demand and the increased efforts in popular science promotion have stimulated and driven the consumption of probiotic health foods, which still hold great potential for development in the future." Zhang Jian added. On the other hand, probiotics have a very bright prospect in modern pharmaceutical industry and agricultural applications related to animals and plants, with rapid growth in recent years.   2022 In China, probiotics in food and beverages accounted for approximately 63.0% Probiotics in health care account for about [X]% of the entire market 15.0% Probiotics for pharmaceutical use account for about half of the market 10.0% Probiotics in other fields such as animal feed, daily necessities, etc., account for about the entire market 12.0% .   Zhang Jian pointed out that the segmentation of the probiotic market is gradually increasing, and in the future, it can be expanded and applied in many niche areas such as scientific research services, clinical nutrition, ecological agriculture, and more. Looking at the entire probiotic industry, the industrial chain can be clearly divided into three parts: upstream, midstream, and downstream. The upstream of the probiotic industry mainly revolves around the sales of probiotic raw materials and is closely related to probiotic patent applications and technical solutions for probiotic products. The downstream, on the other hand, mainly produces products such as food and beverage probiotics, dietary supplements, pharmaceuticals, and probiotics for animals and plants. Subsequently, Zhang Jian analyzed the four major development trends in China's probiotic industry:   ·            Trend 1: Research and Innovation Domestic and international scholars have conducted extensive scientific research on probiotics in terms of resources, efficacy, mechanism of action, safety, delivery, and encapsulation technology. This has led to the emergence of many new academic viewpoints and achievements, further promoting the continuous progress and development of probiotic research. The combination of highly active multi-strain strains has become the mainstream research direction. With the continuous deepening of probiotic research, it is expected that they will play more and greater roles in the future.   ·            Trend 2: Technological Progress The production process of probiotics directly determines the efficacy and quality of the product. With the advancement of biotechnology, probiotic research companies have developed microencapsulation protection technology and spray freeze-drying technology, aiming to increase the viable bacterial content of probiotics when they enter the intestine and maintain their activity; there are also radiation protection and other innovative technologies that play a certain role in assisting in the healing of diseases. In the future, probiotics still need to make further breakthroughs in some key industrial application technologies, such as high-density culture technology, high-activity preparation, and high-stability maintenance technology. ·            Trend 3: Functionalization With the increasing health awareness of consumers and their understanding of probiotics, functional probiotic products targeting specific demographics are rapidly emerging. Children, the elderly, and athletes are becoming important consumer groups. Their needs, such as improving immune system function, emotional health, and resistance to radiation damage, continuously push the boundaries of probiotic functionality. Industry participants like Weikang Probiotics have studied the therapeutic effects of composite probiotics on radioactive intestinal injury, showing certain functions such as improving radiation-induced intestinal injury and regulating the balance of intestinal microecological flora. In the future, the industry will embrace broader development and innovation opportunities. ·            Trend 4: Product diversification The widespread application of probiotics is not limited to dietary supplements but has expanded to multiple different products and industries, bringing differentiated advantages to these products. In addition to early dietary supplements, probiotics are found in cross-category foods such as dairy products, soda, coffee, and even in daily necessities like toothpaste, facial cleanser, and shampoo. Such changes have enabled probiotics to be accepted by more diverse types of end-users. Incorporating new health concepts into the highly competitive market has become an important logic for creating blockbuster products. As the best growth partner with industry depth and breadth, Frost & Sullivan serves leading industry participants across various sectors, covering stages from market strategic positioning to promotional assistance. The Greater China Consumer Goods Industry Group of Frost & Sullivan serves leading enterprises in various sub-sectors and industries related to the consumer goods industry (including clothing, food, housing, transportation, culture, education, entertainment, etc.), dedicated to exploring growth strategies for both industries and businesses together with industry leaders.